TVRD ▲ +3.8% - Tvardi Therapeutics, Inc. $TVRD - New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) 24-SEP-2026 08:00 AM ET